We further showed that silencing DR6 attenuated the malignancy of CRC cells by dampening the AKT/NF-κB signaling pathway, suggesting that DR6 is a positive regulator of AKT/NF-κB signaling in CRC cells. This evidence concerns the gene NFKB1 and colorectal carcinoma.